Compare Gilead Sciences, Inc. (GILD) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs United Airlines Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $134.68 (market cap $163.51B), while United Airlines Holdings Inc trades at $119.24 (market cap $39.26B). The key difference: Gilead Sciences, Inc. is far larger — about 4.2× United Airlines Holdings Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals.
| GILD | UAL | |
|---|---|---|
Market Cap | $163.51B | $39.26B |
Sector | Health | Industrials |
52-Week High | $155.80 | $136.11 |
52-Week Low | $108.22 | $84.57 |
Enterprise Value | $178.05B | $56.29B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
United Airlines (UAL) trades at $117.9, down 2.01% on the day, with a bullish technical signal supported by oversold RSI readings and a consensus analyst price target of $160.88. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $2.46 surpassing expectations, while revenue growth remains steady and profitability metrics like ROE of 25.73% show strong performance. Recent news highlights a raised full-year adjusted EPS guidance to $9-$11 for 2026 despite a $6 billion fuel cost headwind.
The outlook for UAL is positive given earnings momentum and analyst optimism, but significant risks include volatile fuel prices and macroeconomic pressures. Investment opportunity lies in the stock's attractive valuation with a P/E of 11.33 and potential upside to the consensus target, though investors must weigh fuel cost inflation against travel demand resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
